Contraception
Volume 79, Issue 2 , Pages 139-145, February 2009

Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cells☆☆☆

  • Chainarong Choksuchat

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • Faculty of Medicine, Department of Obstetrics and Gynecology, Prince of Songkla University, Hat-Yai, Songkhla 90110, Thailand
    • ,
  • Shumei Zhao

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • ,
  • Todd D. Deutch

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • ,
  • Thomas D. Kimble

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • ,
  • David F. Archer

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 757 446 7444; fax: +1 757 446 8998.

Received 7 August 2008; received in revised form 27 August 2008; accepted 28 August 2008. published online 10 October 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ The research was supported in part by National Institutes of Health Grant R01 HD43175-01 and CONRAD Clinical Research Center Internal Funds.

☆☆ Conflict of interest: C.C. has nothing to disclose. S.Z. has nothing to disclose. T.D.D. has nothing to disclose. T.D.K. has nothing to disclose. D.F.A. has received research funding from Wyeth, Novo Nordisk, Bayer Healthcare, Warner Chilcott and Glaxo SmithKline; has served as a consultant to Wyeth, Bayer Healthcare, Novo Nordisk, Schering Plough, Merck, Warner Chilcott, Abbott Laboratories, and Agile Therapeutics and has received honoraria from Organon, Wyeth, Novo Nordisk and Ascend Therapeutics.

PII: S0010-7824(08)00449-6

doi:10.1016/j.contraception.2008.08.008

Contraception
Volume 79, Issue 2 , Pages 139-145, February 2009

Article Tools

* Image Usage & Resolution